Gm2 Gangliosidosis clinical trials

Explore recruiting gm2 gangliosidosis clinical trials.

Recruiting gm2 gangliosidosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gm2 Gangliosidosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis

France, Portugal, Germany, Italy, Spain, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

Gm2 Gangliosidosis trials by city

Gm2 Gangliosidosis in Toronto Gm2 Gangliosidosis in Vancouver Gm2 Gangliosidosis in Montreal Gm2 Gangliosidosis in Calgary Gm2 Gangliosidosis in Edmonton Gm2 Gangliosidosis in Ottawa Gm2 Gangliosidosis in Winnipeg Gm2 Gangliosidosis in Quebec City Gm2 Gangliosidosis in Hamilton Gm2 Gangliosidosis in Kitchener Gm2 Gangliosidosis in London Gm2 Gangliosidosis in Halifax Gm2 Gangliosidosis in New York Gm2 Gangliosidosis in Los Angeles Gm2 Gangliosidosis in Chicago Gm2 Gangliosidosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease